Skip to content
Screener

Viking Therapeutics VKTX Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$3.42M+145%
VAN
Vivani MedicalVANI
$18.28M-3.5%

Other financials

Income statement

See full
Revenue-
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$3.88B+8.4%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0.0×
Current ratio5.7×-38.5×

Where this comes from

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.

Filed
Apr 29, 2026, 9:50 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-193315
Line itemMarch 31, 2026December 31, 2025
Right-of-use assets$85
Lease liability obligations, current$137
Lease liability obligations, less current portion
Total lease liability obligations$137
Weighted-average remaining lease term0 years0.25 years
Weighted-average discount rate6.28%

Item 1. Financial Statements

FAQ

What is Viking Therapeutics's operating lease liabilities (total)?
Viking Therapeutics (VKTX) reported operating lease liabilities (total) of $0 in Q1 2026.
How has Viking Therapeutics's operating lease liabilities (total) changed year-over-year?
Viking Therapeutics's operating lease liabilities (total) decreased by 100.0% year-over-year, from $1M to $0.
What is the long-term trend for Viking Therapeutics's operating lease liabilities (total)?
Over 5 years (2020 to 2025), Viking Therapeutics's operating lease liabilities (total) has grown at a -17.5% compound annual growth rate (CAGR), from $359K to $137K.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.

Ask your AI about Viking Therapeutics's operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude